trending Market Intelligence /marketintelligence/en/news-insights/trending/EI9wGAeMyZC0QAey1boM5Q2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Teva seeks US FDA approval for migraine treatment

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Teva seeks US FDA approval for migraine treatment

Teva Pharmaceutical Industries Ltd. filed a biologics license application, seeking approval for its migraine treatment fremanezumab from the U.S. Food and Drug Administration.

The submission is supported by the results of two phase 3 trials that involved patients with episodic and chronic migraine. The drug met its primary and secondary endpoints reducing the number of migraine days.

Fremanezumab is a fully humanized monoclonal antibody targeting the calcitonin gene-related peptide ligand, a well-validated target in migraine.